Onconetix Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

David White

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	3.7yrs
Gemiddelde ambtstermijn bestuur	less than a year

Recente managementupdates

Recent updates

Analyseartikel • Jan 24

Here's Why We're Not Too Worried About Blue Water Vaccines' (NASDAQ:BWV) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Seeking Alpha • Oct 11

Blue Water plans to evaluate BWV-201 vaccine for pneumococcal pneumonia

Blue Water Vaccines (NASDAQ:BWV) said it plans to evaluate BWV-201, its Streptococcus pneumoniae ((SP) vaccine candidate to prevent acute otitis media (AOM), to also protect against non-invasive pneumococcal pneumonia. Otitis media is inflammation in the middle ear. SP are gram-positive anaerobic bacteria. Non-invasive forms of pneumococcal disease include AOM, sinusitis, and pneumococcal pneumonia, while invasive forms include bacteremia, sepsis, and pneumococcal meningitis, the company said in an Oct. 11 press release. Blue Water noted that BWV-201 is a live attenuated bacterial vaccine candidate developed to prevent AOM in children caused by SP. New data, based on experiments at St. Jude Children’s Research Hospital, suggested that BWV-201 may also provide protection against pneumococcal pneumonia by limiting the ability of SP to infect the lungs. "With this new data, we believe our vaccine can provide protection across all Streptococcus pneumoniae strains and eliminate the need for antibiotic treatment associated with pneumococcal pneumonia," said Blue Water Chairman and CEO Joseph Hernandez.

Seeking Alpha • Aug 17

Blue Water Vaccines stock jumps ~22% premarket on plans to develop monkeypox shot

U.S. vaccine maker Blue Water Vaccines (NASDAQ:BWV) on Wednesday said it plans to potentially develop a monkeypox shot using its technology, sending its shares surging 22.4% to $3.12 in premarket trading. Cincinnati, Ohio.-based BWV said it would develop the vaccine using its norovirus shell and protrusion virus-like particle platform. The company is already using the platform to develop vaccines for multiple diseases, including flu and malaria. Blue Water's (BWV) announcement comes at a time when the current monkeypox outbreak has been declared a public emergency by both the U.S. FDA and the World Health Organization. According to the U.S. Centers for Disease Control and Prevention, there are a total of about 12.7K confirmed monkeypox cases as of Aug. 16 across the country. The U.S. is using two vaccines for the prevention of monkeypox - Bavarian Nordic's (OTCPK:BVNKF) (OTCPK:BVNRY) Jynneos shot and Sanofi's (SNY) ACAM2000 shot. Other vaccine developers targeting monkeypox: Emergent BioSolutions (EBS), Chimerix (CMRX).

Seeking Alpha • Jul 20

Blue Water Vaccines in pact to study Alzheimer’s vaccine

Newly IPO’d biotech Blue Water Vaccines (NASDAQ:BWV) announced a sponsored research agreement with Cincinnati Children’s Hospital Medical Center on Wednesday to study vaccine candidates for conditions such as Alzheimer’s. The news sent company shares more than 11% higher in late trading. In July 2021, Cincinnati Children’s and Blue Water Vaccines (BWV) inked a global licensing agreement to jointly develop vaccines targeted at multiple indications using the Medical Center's virus-like particle (VLP) vaccine platform. Under the previous agreement, the parties have led studies for BWV-301 in gastroenteritis caused by norovirus or rotavirus. With the new partnership, Blue Water Vaccines (BWV) has agreed to fund studies to explore the potential of the platform in other conditions such as influenza and Alzheimer’s disease. Since its public debut in February, the Cincinnati, Ohio-based vaccine developer has lost ~97%, as shown in this graph.

Seeking Alpha • May 17

Blue Water Vaccines: Estimates And Expectations

Blue Water Vaccines has a long road ahead of it. The company has multiple drug candidates in its pipeline but has not yet started clinical trials. Getting any particular vaccine through phase 3 trials will likely cost at least $40mm and take at least six years. On the positive side, vaccines have one of the highest approval probabilities of any type of drug. The expected value of an investment today is positive, but the odds of success are only about 33%.

CEO

David White (72 yo)

less than a year

Tenure

Mr. David Allan White, CPA, CA, ICD D, is Chief Executive Officer of Onconetix, Inc. from March 18, 2026. He served as Chief Executive Officer of American Student Transportation Partners.He served as an I...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Karina Fedasz	Interim Chief Financial Officer	1.9yrs	US$352.06k	geen gegevens
David White	Chief Executive Officer	less than a year	geen gegevens	geen gegevens
Andrew Skibo	Global Head of Biologics Operations	4.9yrs	geen gegevens	geen gegevens
Brian Price	Head of Technology Strategy	5.7yrs	US$126.48k	geen gegevens
Theodore Yoho	Head of Business Development	4.9yrs	geen gegevens	geen gegevens
Ali Fattom	Head of Science & Discovery	3.7yrs	geen gegevens	geen gegevens
Jay Newmark	Chief Medical Officer	3.1yrs	geen gegevens	geen gegevens

3.7yrs

Gemiddelde duur

Ervaren management: Het managementteam van ONCO wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.7 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
John Rice	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Sarah Romano	Non-Executive Director	less than a year	US$4.95k	geen gegevens
Sunetra Gupta	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Samuel Dorf	Chairman of Board	less than a year	geen gegevens	geen gegevens
Joshua Epstein	Independent Director	less than a year	geen gegevens	geen gegevens

0.2yrs

Gemiddelde duur

45yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ONCO wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.2 jaar), wat duidt op een nieuw bestuur.

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2026/05/21 12:47
Aandelenkoers aan het einde van de dag	2026/05/20 00:00
Inkomsten	2026/03/31
Jaarlijkse inkomsten	2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Onconetix, Inc. wordt gevolgd door 2 analisten. 0 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Vernon Bernardino	H.C. Wainwright & Co.
Jason McCarthy	Maxim Group

Onconetix Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Less than half of directors are independent

High number of new directors

Onconetix, Inc., Annual General Meeting, Dec 05, 2025

High number of new and inexperienced directors

Onconetix, Inc. Appoints Karina Fedasz as Interim Chief Executive Officer

Onconetix, Inc., Annual General Meeting, Jun 04, 2025

Recent updates

Onconetix, Inc. Announces 1-For-10 Reverse Stock Split to Maintain Compliance with the Minimum Bid Price Requirement

First quarter 2026 earnings released: US$6.71 loss per share (vs US$197 loss in 1Q 2025)

Less than half of directors are independent

New major risk - Financial position

Full year 2025 earnings released: US$16.56 loss per share (vs US$1,823 loss in FY 2024)

Realbotix, LLC entered into a Share Exchange Agreement to acquire Onconetix, Inc. (NasdaqCM:ONCO) in a reverse merger transaction.

New major risk - Share price stability

High number of new directors

Onconetix, Inc., Annual General Meeting, Dec 05, 2025

Second quarter 2025 earnings released

High number of new and inexperienced directors

Onconetix Receives Deficiency Notice from Nasdaq Regarding Listing Rules

Onconetix Announces Receipt of Additional Notice from Nasdaq

Ocuvex Therapeutics, Inc. signed a Non-Binding Letter of Intent to acquire Onconetix, Inc. (NasdaqCM:ONCO) in a reverse merger transaction.

Onconetix, Inc. Appoints Karina Fedasz as Interim Chief Executive Officer

Onconetix, Inc. announced delayed annual 10-K filing

Onconetix, Inc. Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish Cohort

Onconetix, Inc., Annual General Meeting, Jun 04, 2025

Onconetix, Inc. Announces Resignation of Ralph Schiess as Interim Chief Executive Officer

High number of new and inexperienced directors

Onconetix Receives Non-Compliance Letter from Nasdaq Regarding Bid Price Rule

Onconetix Provides Non-Compliance Update with Listing Rule 5250(c)(1)

Onconetix, Inc. announced delayed 10-Q filing

High number of new and inexperienced directors

Onconetix Receives Deficiency Notice from the Nasdaq Regarding Listing Rule 5550(a)(1)

Onconetix, Inc. announced that it expects to receive $27 million in funding

Onconetix Provides Non-Compliance Update

Onconetix, Inc. announced that it expects to receive $5 million in funding

Onconetix, Inc. announced delayed 10-Q filing

Onconetix, Inc., Annual General Meeting, Sep 05, 2024

Onconetix, Inc. announced delayed 10-Q filing

Onconetix Receives Deficiency Notice from the Nasdaq Regarding Listing Rule 5550(b)(1)

Onconetix, Inc. announced delayed annual 10-K filing

High number of new and inexperienced directors

High number of new and inexperienced directors

Onconetix, Inc. Announces Appointment of Ajit Singh to its Board of Directors

Onconetix, Inc. Announces Chief Executive Officer Changes

Onconetix, Inc. Announces Resignation of Erin Henderson as Chief Business Officer

Onconetix, Inc. Announces Executive Appointments

Onconetix, Inc.(NasdaqCM:ONCO) dropped from NASDAQ Composite Index

Blue Water Biotech, Inc. (NasdaqCM:BWV) acquired ProteoMediX AG.

Blue Water Biotech, Inc. announced delayed 10-Q filing

High number of new and inexperienced directors

Blue Water Biotech, Inc. Appoints Dr. Neil J. Campbell as CEO

Blue Water Biotech Receives Non-Compliance Notice from Nasdaq

Blue Water Biotech, Inc. Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q

Blue Water Biotech, Inc. Announces Executive Changes

Blue Water Biotech, Inc. announced delayed 10-Q filing

New major risk - Shareholder dilution

Blue Water Biotech Secures License from Ohio State Board of Pharmacy to Operate as Pharmaceutical Wholesaler for Its FDA Approved Products

Blue Water Biotech, Inc. Announces Preliminary Preclinical Data Supporting the Use of Its Norovirus Shell and Plusion Virus-Like Particle Platform to Develop Novel Monkeypox Vaccine Candidate

New major risk - Share price stability

Blue Water Biotech, Inc. (NasdaqCM:BWV) agreed to acquire Six FDA Approved Drugs from WraSer LLC and Xspire Pharma, LLC.

New major risk - Financial position

Blue Water Vaccines, Inc. Appoints Frank Jaeger as Senior Vice President of Marketing and Business Development

Here's Why We're Not Too Worried About Blue Water Vaccines' (NASDAQ:BWV) Cash Burn Situation

Blue Water Vaccines Appoints Timothy Ramdeen to Its Board of Directors

High number of new and inexperienced directors

Blue Water plans to evaluate BWV-201 vaccine for pneumococcal pneumonia

CEO, President & Executive Chairman recently sold US$2.6m worth of stock

CEO, President & Executive Chairman notifies of intention to sell stock

Blue Water Vaccines stock jumps ~22% premarket on plans to develop monkeypox shot

Blue Water Vaccines in pact to study Alzheimer’s vaccine

Blue Water Vaccines: Estimates And Expectations

High number of new and inexperienced directors

CEO

Leiderschapsteam

Bestuursleden

Bedrijfsanalyse en status van financiële gegevens